| Assessment Status | Rapid Review Complete |
| HTA ID | 25036 |
| Drug | Nivolumab (Opdivo®) |
| Brand | Opdivo® |
| Indication | Nivolumab (Opdivo®) for subcutaneous (SC) use co-formulated with recombinant human hyaluronidase (rHuPH20), is indicated across multiple previously approved adult solid tumours as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab (Yervoy®) combination therapy, or in combination with chemotherapy or cabozantinib. |
| Assessment Process | |
| Rapid review commissioned | 19/05/2025 |
| Rapid review completed | 18/06/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that nivolumab (Opdivo®) SC not be considered for reimbursement at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here